MiR-21 influences this process by upregulating M2 markers (like CD206 and IL-10) and downregulating M1 markers (such as TNF-α and iNOS), thus driving macrophages toward the tumor-promoting M2 phenotype. The gene discussed is IL10; the disease is neoplasm.